Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. - Wikidata - wikimedia - TriplyDB

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

http://www.wikidata.org/entity/Q37090971

about

Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies Animal Models and "Omics" Technologies for Identification of Novel Biomarkers and Drug Targets to Prevent Heart Failure Biomarker as a research tool in linking exposure to air particles and respiratory health Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs Myocardial fibrosis: biomedical research from bench to bedside.Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials.Nutrition intervention to decrease symptoms in patients with advanced heart failure.Toll-like receptor 9 mediated responses in cardiac fibroblasts Lycopene dietary intervention: a pilot study in patients with heart failure Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure.Shenfu Injection suppresses inflammation by targeting haptoglobin and pentraxin 3 in rats with chronic ischemic heart failure.Association between red blood cell distribution width and acute pancreatitis.Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction.The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction.Effects of obesity on the association between long-term sleep apnea treatment and changes in interleukin-6 levels: the Icelandic Sleep Apnea Cohort.Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy.Hypoalbuminaemia and incident heart failure in older adults.Melatonin protects against myocardial hypertrophy induced by lipopolysaccharide.Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.Evaluation of adenosine deaminase (ADA) isoenzymes activity and tumor necrosis factor-α (TNFα) concentration in chronic heart failure Inflammation, Endothelial Dysfunction and Increased Left Ventricular Mass in Chronic Kidney Disease (CKD) Patients: A Longitudinal Study Inflammation and cardiac outcome Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.MicroRNA therapeutics in cardiovascular medicine.Prognostic Utility of Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients with Severe Calcific Aortic Stenosis.Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy Identifying panaxynol, a natural activator of nuclear factor erythroid-2 related factor 2 (Nrf2) from American ginseng as a suppressor of inflamed macrophage-induced cardiomyocyte hypertrophy.Drug target identification using network analysis: Taking active components in Sini decoction as an example.How can we cure a heart "in flame"? A translational view on inflammation in heart failure.Is CaMKII a link between inflammation and hypertrophy in heart?Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators?An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes.Molecular Characterization of Pediatric Restrictive Cardiomyopathy from Integrative Genomics Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?Multiple cytokine biomarkers in heart failure.Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation.Cardiorenal syndrome: diagnosis, treatment, and clinical outcomes.Therapeutic targeting of innate immunity in the failing heart.

P2860

Q26746907-9EE40E24-9B5B-4762-8DC3-E3CC41C54A65 Q26799838-0956D8A7-1D16-458F-BABA-4EA867ADC4B4 Q27012783-6B9632DC-6C2C-4A54-8AA2-2B034DD8688C Q28077186-92CF0F19-866A-4A6C-853B-DE45252E1C62 Q28085736-BD92D4C7-56D3-4D72-A8AE-A451587A587F Q30362840-DDA4481B-F779-4193-BE15-ABF8E1AB1E4D Q31096498-E497129A-CF2B-48F1-B0C0-02F7328CE277 Q33572474-FB8C965E-D28F-40A0-B5CB-44EF89C90D45 Q34050642-D7B107D9-AF6D-4436-A116-2539A8EE984A Q34207466-6FE2F25C-639E-4F82-BA34-7E2B89A414FB Q34498176-CF66E3F8-045B-464E-91BF-A1DF3A9F79FF Q34620837-8FF2B56A-B207-4CE6-B388-319694D0FEF5 Q34639226-3F080D7D-E868-4BBA-9CA7-F5439C72DBF8 Q35026270-B7EED1D2-962B-4DC7-BBE8-8B4E35F4D980 Q35072339-70C1D9AA-59FE-4879-95F1-C6968C3088A6 Q35152108-4B51CC47-62BC-4D16-8280-6043C18D2C4C Q35177936-E3BC0239-D299-4CE7-A713-DE00AFDC9377 Q35224984-00207948-0787-495F-B620-EFFF4B5B69DB Q35490630-F904B970-7C5B-43F3-9AFF-4A89457A51B6 Q35534909-4456897F-8555-4ED8-8EA2-657F83B28675 Q35721547-B0D0E77F-6AB7-4F32-A3F4-FD02DF1FBDBA Q35784920-15CF9C6E-3CA9-4122-9EEF-D8A70C39D1B1 Q35835539-93D88D5F-31EE-4D22-AB25-4057C10EB4F7 Q36022217-84EFE78B-4BAF-49AB-83CD-5456C269C8C2 Q36037919-4C934CB0-BFAA-41F0-8B85-6209B20D6EFC Q36109103-C13356F7-BEB6-48A6-863C-C8C0B34DFFCE Q36647124-55612B44-5645-4027-BAB2-64C28FD983D7 Q36736742-6885E09D-F3A5-4C3A-931F-7BC3249AF333 Q36814771-A60E15E7-A71E-4072-8FA3-75C00BBB09AD Q37004826-0DA85F85-1199-4B7D-9FCF-2B1BE9F6B151 Q37064322-F7C16B87-33E9-4CAB-8FB4-28A089B56C66 Q37292234-B14DB0CA-6183-4C15-A559-A1E13127E36C Q37413342-E180DC00-44DE-4CAF-8F15-AA1C343AF70B Q37576766-BF660001-CD62-478C-89D3-0B3A30D6D989 Q37591259-F35B73A2-80E1-42B8-93FB-28900D65524F Q37608787-E2D06312-0EC1-4BB9-9E42-5087182B474C Q37705430-23F148ED-A873-4AE6-A2F7-CA6D03912ABF Q37775559-FEA90FA9-F821-4F87-9A0F-4F4A372CBAFD Q37782283-D303ACF2-3BFC-4E3A-8CC3-ED183847312C Q37809215-CB604919-9848-4C83-B7D2-F7533020DA09

P2860

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

http://www.wikidata.org/entity/Q37090971

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inflammation as a therapeutic ...... uropean Society of Cardiology.

@en

Inflammation as a therapeutic ...... uropean Society of Cardiology.

@nl

type

label

Inflammation as a therapeutic ...... uropean Society of Cardiology.

@en

Inflammation as a therapeutic ...... uropean Society of Cardiology.

@nl

prefLabel

Inflammation as a therapeutic ...... uropean Society of Cardiology.

@en

Inflammation as a therapeutic ...... uropean Society of Cardiology.

@nl

P1433

Q37090971-C0609024-C5D7-44D7-B7A5-778224CCD38B

P1476

Q37090971-B3395AFD-E877-43FF-AF13-5AAA18172FEC

P2093

Q37090971-1F748C99-A935-4F55-864D-DB675D680D2F

Q37090971-396326C3-81C2-4EFC-BEAC-394005042C83

Q37090971-3B645E08-32B3-471B-9521-C68836DAA2CE

Q37090971-56B616CD-1DF8-47A8-8564-78CD213A3A23

Q37090971-73CD1B2A-3DED-4FF6-8732-E564B2FA06C4

Q37090971-7C3951E1-B642-4FF6-93B6-7643789F3061

Q37090971-83FB2ED9-8083-46A0-8C4B-0EE8D91B7CEC

Q37090971-ABCAF24F-1907-4238-8AB8-91191E7C271D

Q37090971-F0B46BBD-D918-421D-B4F5-97977042FA9A

Q37090971-F12B76CD-F0BC-4016-B6AC-D89CFBEC3325

P2860

Q37090971-010B1E04-CAC3-4E3E-A21D-B161F82A6662

Q37090971-02A2F2AA-EEF0-4B50-B366-3498544790CF

Q37090971-04DF3BDA-EDA4-4E68-9304-B07D1F3FFD76

Q37090971-07F6BA14-5D44-4545-B684-FB338D83FE29

Q37090971-08165569-9B1F-4AB6-88DD-1B15E51CCF7D

Q37090971-0C24B013-B9F4-41B1-9E5C-EF5478B50591

Q37090971-0EFC7AEE-8A2D-4355-A543-823C09CECDF1

Q37090971-0F71990C-3225-4DE7-ADB8-E74708A141CD

Q37090971-12E67B8A-3184-434E-8503-847FFD3207BC

Q37090971-1361246E-4FD7-4E52-8F77-1AF707C92AF7

P304

Q37090971-BAB640A4-9DDF-4883-8F1F-F844121DEE11

P31

Q37090971-65544A33-AC13-4EB6-A56D-F7265A565D7E

P356

Q37090971-9AD0F3BA-22E7-4598-8706-16D172BA9C18

P433

Q37090971-E8ADFA8D-4551-4E22-A581-886C2B3D7175

P478

Q37090971-FA7B1A0E-4AD2-4556-8B4E-4279C60E4742

P50

Q37090971-0210D8F3-0930-45ED-934E-0711287FDE3E

Q37090971-0CA5D3B4-DE02-4607-AB2F-BD16962A7CE1

Q37090971-1081CCAC-E00B-4CE1-B1F3-418424DF014F

Q37090971-191859AE-29EE-46D4-AED8-71EFFFB956CB

Q37090971-4096F7D1-2CAD-4457-9D45-B12BB3A39115

Q37090971-4B7BACB6-A205-48F5-914F-3991EA376439

Q37090971-509433D7-406F-43D5-8018-64572FC6474F

Q37090971-551B7B3B-D47C-4DBE-BCE7-381B7BD3F16C

Q37090971-6C4B99DA-2287-4D9D-BAC8-9DA58E8CE953

Q37090971-7A124FC6-8E17-4238-9BD9-451D41414315

P577

Q37090971-971BC7DE-8A81-4A81-BC61-0D8DFA1321A8

P5875

Q37090971-8510DD7C-1E94-48D5-95E0-DA9D586D57A1

P698

Q37090971-957DA1EF-28FD-4263-9C6C-F721052E3643

P921

Q37090971-E130115E-FAA3-4EC8-AFD2-32965F43719C

Q37090971-EAB3DA9B-BA97-4F9D-9EA2-E9651C44C6A5

P932

Q37090971-54165BD5-C362-4FF7-8C17-A70A0EF81D39

P356

P1433

European Journal of Heart Failure

P1476

Inflammation as a therapeutic ...... uropean Society of Cardiology.

@en

P2093

Blanche Schroen

http://www.w3.org/2001/XMLSchema#string

Carsten Tschöpe

http://www.w3.org/2001/XMLSchema#string

Heinz-Peter Schultheiss

http://www.w3.org/2001/XMLSchema#string

Helmut Drexler

http://www.w3.org/2001/XMLSchema#string

Jan W Cohen-Tervaert

http://www.w3.org/2001/XMLSchema#string

Marc Van Bilsen

http://www.w3.org/2001/XMLSchema#string

Roberto Latini

http://www.w3.org/2001/XMLSchema#string

Stefan Janssens

http://www.w3.org/2001/XMLSchema#string

Stephan B Felix

http://www.w3.org/2001/XMLSchema#string

Stephane Heymans

http://www.w3.org/2001/XMLSchema#string

P2860

The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts

Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior

Acute viral myocarditis

Thrombospondin-2 Is Essential for Myocardial Matrix Integrity: Increased Expression Identifies Failure-Prone Cardiac Hypertrophy

Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress

Stroke prevention in diabetes and obesity

Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling

Active Coxsackieviral B infection is associated with disruption of dystrophin in endomyocardial tissue of patients who died suddenly of acute myocardial infarction

Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption.

Is microvascular flow rate related to ghrelin, leptin and adiponectin levels?

P304

119-129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFN043

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Piotr Ponikowski

Stefan D. Anker

Denise Hilfiker-Kleiner

Jean-Luc Balligand

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23938821

http://www.w3.org/2001/XMLSchema#string

P698

19168509

http://www.w3.org/2001/XMLSchema#string

P921

P932

2639409

http://www.w3.org/2001/XMLSchema#string